Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31382245 | 1.00 | CRBN (0.55) | CRBNDDB1POLBNOTUMAKR1C3 | |
| SCHEMBL25195064 | 1.00 | CRBN (0.55) | CRBNDDB1POLBNOTUMAKR1C3 | |
| SCHEMBL31382100 | 1.00 | CRBN (0.55) | CRBNDDB1POLBNOTUMAKR1C3 | |
| Hydrochloric Acid SCHEMBL31381896 | 0.99 | CRBN (0.54) | CRBNDDB1POLBNOTUMAKR1C3 | |
| SCHEMBL25193849 | 0.93 | CRBN (0.48) | CRBNDDB1POLBNOTUMAKR1C3 | |
| SCHEMBL24207803 | 0.93 | NOTUM (0.55) | CRBNDDB1POLBNOTUM | |
| SCHEMBL27342294 | 0.93 | NOTUM (0.55) | CRBNDDB1POLBNOTUM | |
| SCHEMBL30981325 | 0.90 | CRBN (0.47) | CRBNDDB1POLBAKR1C3 | |
| SCHEMBL25184931 | 0.89 | CRBN (0.46) | CRBNDDB1POLBNOTUMAKR1C3 | |
| SCHEMBL25191723 | 0.89 | CRBN (0.46) | CRBNDDB1POLBNOTUMAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | CRBN 104/4885DDB1 321/4885POLB 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.